Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Reports Positive Preclinical Data for Nasal Anti-CD3 in Age-Related Cognitive Decline

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.22
Mkt Cap
$139.057M
52W Low
$0.73
52W High
$2.6
52W Position info
67% above low
Off High info
53% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

TLSA sits 67% above its 52-week low of $0.73.

Summary

Tiziana Life Sciences announced positive preclinical data for its lead candidate, nasal anti-CD3, showing its potential to reverse brain aging and improve cognition by reducing neuroinflammation.


Key Events · Product Development and Regulatory · TLSA

  • Positive Preclinical Data Announced

    Nasal anti-CD3 demonstrated potential to address neuroinflammation associated with aging, reverse key aspects of brain aging, and improve cognition in preclinical studies.

  • Mechanism of Action Reinforced

    Key study findings indicate nasal anti-CD3 dampens microglial activation and enhances neurogenesis in the hippocampus, supporting its role in modulating the immune system to reduce neuroinflammation.

  • Expanded Therapeutic Potential

    The data suggests potential applications for intranasal foralumab in age-related cognitive impairment, broadening its scope beyond ongoing clinical trials in other neurodegenerative indications.


Analysis · TLSA · Life Sciences

This filing announces positive preclinical data for Tiziana's lead candidate, nasal anti-CD3 (foralumab), demonstrating its potential to address neuroinflammation associated with aging and improve cognition. The data reinforces the drug's mechanism of action by showing it dampens microglial activation and enhances neurogenesis in the hippocampus. This expands the potential therapeutic applications for foralumab beyond its current neurodegenerative programs (MS, MSA, ALS, Alzheimer's), suggesting a new, large market opportunity in age-related cognitive impairment. While preclinical, these findings provide a positive signal for the drug's broad utility and could support future clinical development in this area.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSA was trading at $1.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $139.1M. The 52-week trading range was $0.73 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.5677 info
Change: -$0.0572 (-9%) info
Market Cap: $73.123M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.5677 info
Change: -$0.3223 (-36%) info
Market Cap: $73.123M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.5677 info
Change: -$0.3008 (-35%) info
Market Cap: $73.123M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.5677 info
Change: -$0.4823 (-46%) info
Market Cap: $73.123M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.5677 info
Change: -$0.5023 (-47%) info
Market Cap: $73.123M info